A surrogate FRAX model for Pakistan.


Journal

Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988

Informations de publication

Date de publication:
17 02 2021
Historique:
received: 07 12 2020
accepted: 15 01 2021
entrez: 17 2 2021
pubmed: 18 2 2021
medline: 2 3 2021
Statut: epublish

Résumé

A surrogate FRAX® model for Pakistan has been constructed using age-specific hip fracture rates for Indians living in Singapore and age-specific mortality rates from Pakistan. FRAX models are frequently requested for countries with little or no data on the incidence of hip fracture. In such circumstances, the International Society for Clinical Densitometry and International Osteoporosis Foundation have recommended the development of a surrogate FRAX model, based on country-specific mortality data but using fracture data from a country, usually within the region, where fracture rates are considered to be representative of the index country. This paper describes the development and characteristics of a surrogate FRAX model for Pakistan. The FRAX model used the ethnic-specific incidence of hip fracture in Indian men and women living in Singapore, combined with the death risk for Pakistan. The surrogate model gave somewhat lower 10-year fracture probabilities for men and women at all ages compared to the model for Indians from Singapore, reflecting a higher mortality risk in Pakistan. There were very close correlations in fracture probabilities between the surrogate and authentic models (r ≥ 0.998) so that the use of the Pakistan model had little impact on the rank order of risk. It was estimated that 36,524 hip fractures arose in 2015 in individuals over the age of 50 years in Pakistan, with a predicted increase by 214% to 114,820 in 2050. The surrogate FRAX model for Pakistan provides an opportunity to determine fracture probability within the Pakistan population and help guide decisions about treatment.

Identifiants

pubmed: 33595723
doi: 10.1007/s11657-021-00894-w
pii: 10.1007/s11657-021-00894-w
pmc: PMC7889560
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

34

Subventions

Organisme : Department of Health
ID : 10/33/04
Pays : United Kingdom
Organisme : Versus Arthritis
ID : 21231
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_21001
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_21003
Pays : United Kingdom

Références

Osteoporos Int. 2019 Nov;30(11):2225-2230
pubmed: 31372709
Osteoporos Int. 2018 Mar;29(3):707-715
pubmed: 29273826
Arch Osteoporos. 2017 Dec;12(1):43
pubmed: 28425085
Arch Osteoporos. 2013;8:148
pubmed: 23975235
Osteoporos Int. 1999;10(3):240-7
pubmed: 10525717
J Family Med Prim Care. 2019 Jun;8(6):1824-1827
pubmed: 31334139
Osteoporos Int. 2010 Mar;21(3):381-9
pubmed: 19517155
J Bone Miner Res. 2014;29(5):1067-73
pubmed: 24243719
Ann Med Surg (Lond). 2018 Mar 29;29:19-25
pubmed: 29692892
Osteoporos Int. 2012 Sep;23(9):2239-56
pubmed: 22419370
Osteoporos Int. 1999;9(1):29-37
pubmed: 10367027
Aging Clin Exp Res. 2020 Feb;32(2):187-196
pubmed: 32043227
Osteoporos Int. 1994 Sep;4(5):253-63
pubmed: 7812073
Osteoporos Int. 2020 Nov;31(11):2063-2067
pubmed: 32888046
Osteoporos Int. 2014 Oct;25(10):2445-51
pubmed: 24980183
Arch Osteoporos. 2020 Jul 22;15(1):104
pubmed: 32700118
Arch Osteoporos. 2020 May 6;15(1):68
pubmed: 32377964
Osteoporos Int. 2010 Jan;21(1):35-40
pubmed: 19705047
Osteoporos Int. 2005 Nov;16(11):1339-44
pubmed: 15841335
Osteoporos Int. 2001;12(5):417-27
pubmed: 11444092
Osteoporos Int. 2019 Jan;30(1):3-44
pubmed: 30324412
Lijec Vjesn. 2009 Jan-Feb;131(1-2):9-13
pubmed: 19348349
Bone. 2020 Apr;133:115253
pubmed: 31987987
J Bone Joint Surg Br. 1998 Mar;80(2):243-8
pubmed: 9546453
Arch Osteoporos. 2020 Jan 28;15(1):13
pubmed: 31993755
Osteoporos Int. 2011 Oct;22(10):2603-10
pubmed: 21249333
Arch Osteoporos. 2018 Oct 31;13(1):118
pubmed: 30382424
Arch Osteoporos. 2016 Dec;11(1):25
pubmed: 27465509
Osteoporos Int. 2008 Apr;19(4):385-97
pubmed: 18292978
J Clin Densitom. 2011 Jul-Sep;14(3):240-62
pubmed: 21810532

Auteurs

G Naureen (G)

Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

H Johansson (H)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.

R Iqbal (R)

Departments of Community Health Sciences and Medicine, Aga Khan University, Karachi, Pakistan.

L Jafri (L)

Department of Pathology & Laboratory Medicine, Aga Khan University, Karachi, Pakistan.

A H Khan (AH)

Department of Pathology & Laboratory Medicine, Aga Khan University, Karachi, Pakistan.

M Umer (M)

Department of Orthopaedics, Aga Khan University, Karachi, Pakistan.

E Liu (E)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

L Vandenput (L)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

M Lorentzon (M)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Geriatric Medicine, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden.

N C Harvey (NC)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK.

E V McCloskey (EV)

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.
Mellanby Centre for Bone Research, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.

J A Kanis (JA)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. w.j.pontefract@sheffield.ac.uk.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. w.j.pontefract@sheffield.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH